S-GROUP
10.5.2023 05:01:34 CEST | Business Wire | Press release
Researchers at the University of Jyväskylä have developed a method for corporations to calculate their biodiversity footprint. The pilot project focused on S Group’s biodiversity footprint. The outcome of the study will be a method freely available to all companies and organisations for the assessment of their impact on nature.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005817/en/
Researchers at the University of Jyväskylä have developed a method for corporations to calculate their biodiversity footprint. The pilot project focused on S Group’s biodiversity footprint. (Photo: Business Wire)
The interim report of the project published now indicates that food and fuels account for most of S Group’s biodiversity footprint, with the majority of the footprint falling on regions beyond Finland’s borders. Utility goods account for a significantly smaller portion—a few per cent—of the biodiversity footprint.
“Companies already routinely calculate their carbon footprints. This project demonstrates that they can also calculate their biodiversity footprint. A company like S Group, with operations in several different sectors, played a key role in the method’s development,” says Janne Kotiaho, Professor of Ecology at the University of Jyväskylä.
“You have to tackle climate and biodiversity challenges hand in hand. As opposed to climate efforts, biodiversity impacts are very local. The report shows that there is a need for increasingly strong cooperation between businesses and partners operating within the same geographic area. Companies must also start building new kinds of cooperation networks to reduce their negative impact on nature,” says Nina Elomaa, Senior Vice President, Sustainability, at S Group.
“You cannot manage something that you can’t measure. Stopping biodiversity loss requires a functional method for calculating biodiversity footprints. Any company that intends to make a serious effort to manage their biodiversity impact needs a method of this kind. We can take some national pride in Finland being at the forefront of this global development work,” says Lasse Miettinen, Director of Sustainability solutions at Sitra.
The theme is topical, given that nations around the world agreed on new international targets for halting biodiversity loss at the Montreal Biodiversity Conference in December. The global biodiversity framework agreed on also stated that, in the future, large and transnational companies should disclose their negative impact on biodiversity.
Biodiversity footprint maps impact on terrestrial and aquatic ecosystems
Through complex supply chains, a large part of the negative environmental impact attributable to Finnish consumption is generated across the globe, beyond Finland’s borders. According to the calculation model based on financial accounting and Finland’s international trade, more than 90 per cent of S Group’s global biodiversity footprint falls on regions outside Finland.
S Group aims to reduce its biodiversity impact through its climate work and by promoting more sustainable consumption and a planetary health diet. Concrete actions include policies related to raw materials and sourcing that aims to protect fish populations, for example, or ensure that no purchases are made from areas sensitive in terms of forest loss.
How S Group’s biodiversity footprint was assessed
The biodiversity footprint of S Group’s value chain and own operations was assessed with a method devised by the University of Jyväskylä School of Resource Wisdom – JYU.Wisdom.
The indicator of the biodiversity footprint is the share of the world’s species at risk of extinction, i.e. the Potentially Disappeared Fraction (PDF) of species. The indicator collects the PDF of various species under a single unit of measurement, similar to carbon footprint assessments, and enables the international comparison of different corporations’ biodiversity footprints.
The method’s further development continues.
For more information:
S Group - S Group (s-ryhma.fi)
JYU.Wisdom − School of Resource Wisdom — University of Jyväskylä
The Finnish Innovation Fund Sitra
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005817/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
